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Interpretation of the expected value of perfect information and 
research recommendations: a systematic review and empirical 
investigation. 
 
Introduction 
The move towards evidence-based decision making has highlighted the importance of rigorous 
information on the value of health care services and has contributed to an increase in the demand for 
clinical research [1, 2]. At the same time, the public budget for research is limited and funding 
organisations such as the National Institute for Health Research in the UK and the National Institutes 
of Health in the US have to make cost-effective choices on which research projects to prioritise and 
fund. [3-5] Allocating funds to research represents an investment of scarce public resources, and this 
has given rise to calls for funding decisions to be informed by explicit evidence on the value of 
research proposals. [6-12] 
A formal framework, with roots in statistical decision theory [13], has been proposed to assess the 
value of information (VOI) to a decision maker in health care. [14, 15] A key VOI measure is the 
‘expected value of perfect information’ (EVPI), which represents the monetary value that can be 
attached to completely eliminating uncertainty in the decision-making process. The EVPI value for an 
individual is defined as the difference between the value associated with a decision made on the 
basis of current information, and the value that could be expected if perfect information were available 
on which a decision could be based. [16] However, a more appropriate comparative measure for the 
value of acquiring further information is the population EVPI, which takes into account the number of 
people who may benefit from the additional research by incorporating measures of both the time 
frame over which the information is expected to retain its usefulness (before, for example, newer 
technologies render the intervention obsolete), and the number of people with the condition.  
EVPI has the potential to be used as a means of assessing research priorities in a funds-limited 
research environment. [17] If the cost of obtaining further information (via a randomised controlled trial 
(RCT), for example) exceeds the EVPI, there is little justification for proceeding with research, and a 
decision maker can be confident that they could not make a better decision by waiting. Thus the EVPI 
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exceeding the cost of running a trial is a necessary condition that must be fulfilled before research can 
be considered potentially worthwhile and represents a maximum amount that a rational decision 
maker should spend on further research. [18] It should be noted that a high EVPI value is not a 
sufficient condition for advising further research, and firm recommendations in favour of further 
research based on the EVPI value alone are inappropriate. More information from expected value of 
sample information (EVSI) studies is required to determine whether a particular piece of research 
should be conducted. [19] However, a recent review of EVI methods and applications found that, 
despite EVSI being the metric of choice for informing decision making, applied calculations are rarer 
than applied EVPI values. [20] It is likely that this imbalance arises because EVSI is both conceptually 
and computationally complex, while EVPI analysis is relatively straightforward to conduct. Given that 
different trials are anticipated to cost different amounts, and the measure that should strictly be used 
to distinguish between those trials worth funding is EVSI, it is possible to see different 
recommendations for similar values of EVPI. For example, Forbes et al recommended further 
research on the basis of an EVPI value of £10.7 million [21], whilst Rogowski et al did not recommend 
further research with an EVPI value of £10.76 million. [22] It is also likely that considerations other 
than the magnitude of EVPI (e.g. disease area of interest, type of outcome used etc.) may be taken 
into account in making research recommendations. 
With this in mind, we conducted a systematic literature review to identify applied VoI studies with the 
aim of investigating how researchers interpret calculated EVPI values when making research 
recommendations. The study explores whether there exists an empirical magnitude of EVPI below 
which no recommendation for further health research is typically made (i.e. whether there is an 
empirical threshold), looks into the degree of consistency across the literature in the 
recommendations for further research for a given level of EVPI, and investigates whether different 
factors, including disease area, country and measure of outcome, may influence recommendations. 
We aim to observe what is happening in practice, in order to improve transparency in discussions 
around decision making. 
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Methods 
The review was carried out in line with widely used recommendations for undertaking systematic 
literature reviews [23] and aimed to retrieve applied studies reporting EVPI calculations. Prior to the 
publication of the methodological description by Claxton and Posnett in 1996 [14], EVPI calculations 
were rarely reported in health economics; therefore, conducting the search from 1990 covers the 
probable extent of relevant literature. From April 2011, the Cancer Drugs Fund came into force in 
England [24]; this altered commissioning attitudes to the acceptable threshold for funding particular 
cancer treatments, and therefore has the potential to alter approaches to funding research. Therefore, 
the period searched was limited to 1990 to 2010 to avoid adding complications to possible 
interpretations. 
Search strategy 
As EVPI calculations are not routinely reported in abstracts and keywords, two different approaches 
to searching the literature were followed. In the first, standard bibliographic databases were searched 
with relatively broad search terms, whilst in the second, full-text searching was performed with tightly 
defined search terms. The bibliographic databases Medline, EMBASE, CINAHL, Web of Science and 
The Cochrane Library (which includes the Cochrane Database of Systematic Reviews, Cochrane 
Central Register of Controlled Trials, Cochrane Methodology Register, Database of Abstracts of 
Reviews of Effects, Health Technology Assessment Database, and the NHS Economic Evaluation 
Database) were searched using a combination of search terms and wildcards to cover the range of 
different value of information phrases. Adding the qualifier “AND cost” significantly improved the 
specificity of the searches without reducing the sensitivity. Full-text searching was undertaken via the 
websites of the journal publishers and suppliers AdisOnline, HighWire Press, IngentaConnect, 
Cambridge Journals Online, ScienceDirect and the UK Health Technology Assessment (HTA) site, 
covering the significant journals in health economics. Full-text searches were also conducted using 
the Google Scholar search engine. Details of the searches undertaken are given in Appendix 1 
(online). 
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Inclusion criteria  
Articles were included if they: reported calculations of one or more measures of the population 
expected value of perfect information; were undertaken as part of an applied study assessing health 
care interventions; were peer-reviewed publications . Articles were excluded if: the EVPI calculation 
was carried out purely to illustrate a methodological point (for example, if the data used were 
manipulated to disguise their origin); the intervention was an environmental health application; the 
article was not written in English.  
Selection process 
Abstracts of identified studies were screened by one author (JT). A 10 percent sample of the 
abstracts was screened by two reviewers (LA and JT) to check for accuracy and consistency; 
disagreements were resolved by discussion. Some articles without EVPI calculations were eliminated 
by consulting health economic assessments in the NHS Economic Evaluation Database (EED) or 
contacting the author. 
For the remaining abstracts, full-text versions were obtained and screened electronically (by JT) 
where possible. Multiple pdf file search functionality was used to search for the word ‘perfect’ in order 
to eliminate articles that would not contain an EVPI calculation. Non-searchable pdfs were identified, 
and these articles were manually scanned for EVPI calculations. For articles containing the word 
‘perfect’, the context was examined to eliminate irrelevant material. A second screening cycle was 
applied to those articles that either did not contain the word ‘perfect’ or contained it in an irrelevant 
context by searching for the word ‘information’. 
A final screening process was undertaken by reading the full text and eliminating articles that did not 
describe an applied EVPI calculation. Some studies were reported twice; only the most recently 
published article was included to maximise the likelihood of a full report. However, the earlier report 
was used to supply additional details where necessary. 
Data extraction 
For each study that met the inclusion criteria, extracted information included background 
characteristics such as publication year, funder, location and disease group based on ICD-10 chapter 
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heading. Both individual and population EVPI values were extracted, along with the willingness-to-pay 
(WTP) threshold (i.e. the hypothetical value that society is willing to pay for an additional unit of health 
outcome), outcome measure and currency. The time frame over which the technology was expected 
to be useful was also noted. Where multiple EVPI values were cited, a pragmatic approach to 
choosing a single value was taken; for example, a value at a WTP of £30,000 (or other commonly 
cited WTP values) was taken where possible, and EVPI values were read from graphs if necessary. 
Finally, brief text excerpts describing the interpretation of the values, recommendations based on the 
values and research prioritisation comments were extracted verbatim.  
The extracted texts were classified according to whether the recommendation was for or against 
further research (i.e. positive or negative), on an ordinal scale of recommendations. The scale ran 
from ‘beneficial’ to do further research (for example, if the technique was said to warrant further 
research or further research was justified), through ‘probably beneficial’ (e.g. if further research was 
considered likely to be worthwhile), ‘possibly beneficial’ (if phrases such as ‘could be cost-effective’ 
were used), ‘possibly not beneficial’ (if research ‘may not be’ cost-effective, for example), ‘probably 
not beneficial’ (for example, if research was considered unlikely to represent an efficient use of 
resources) to ‘not beneficial’ to do further research (e.g. if it was stated that research would not be 
justified).  
Extracted data were used to classify the type of research funder. Population EVPI and WTP values 
were converted to sterling using Bank of England exchange rates, taking the value at 31 December 
(or closest preceding day) of the relevant cost year of the study, or the publication year if unavailable. 
[25] Owing to the complex nature of EVPI calculations with costs bound up in WTP thresholds, and 
the lack of consistent reporting of cost year, it was not possible to convert EVPI values to a common 
cost year. The quality of the articles was not formally assessed and did not form one of the exclusion 
criteria because we were interested in how authors responded to the values that they found rather 
than whether the EVPI calculations were correctly derived. Therefore, articles with methodological 
limitations were not excluded on that basis alone. For example, where an inappropriately large 
population had been used to derive a population EVPI resulting in a hugely inflated value, the study 
was included in the analysis because a recommendation was still made and flowed logically from the 
value calculated.  
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Statistical modelling 
Extracted data provided the basis for exploring possible relationships between authors’ research 
recommendations and various factors, such as country that the study relates to, study funder, disease 
area, year of publication and magnitude of EVPI. As a first step, we used the data to consider 
graphically how these factors may affect research recommendations. In addition, the impact of these 
factors on the dichotomous ‘recommend/not recommend’ outcome variable was explored using 
logistic regression. Briefly, logistic regression models the effect of one or more explanatory variables 
and interaction terms (here, various factors) on the odds of a dichotomous dependent variable (here, 
recommend/not recommend). Different interaction terms were considered on the premise that these 
have a plausible modifying effect on the outcome variable (e.g. interaction between EVPI and country, 
assuming that EVPI may differ according to the country that research relates to). Different model 
specifications were considered using stepwise selection (forward selection and stepwise elimination) 
and hierarchical regression. An unrestricted (full) model containing all the available variables was 
compared to several nested models using the likelihood ratio (LR) test and the Akaike (AIC) and 
Bayesian (BIC) information criteria. [26] An empirical threshold EVPI value was calculated at the point 
where the probability of a positive recommendation is 0.5, holding any covariates in the model fixed at 
their baseline values. [27] Statistical and graphical analyses were performed using Stata 11. [28] 
Results 
The bibliographic database searches identified 2078 potentially relevant articles, while a further 560 
articles were identified via full-text searches. Following deduplication, 2497 abstracts required 
screening. Screening by two reviewers of a 10% sample (250 abstracts) resulted in good agreement 
on inclusion (κ = 0.72). Inspection of the abstracts, consultation of the NHS EED and author contacts 
led to 2032 articles being eliminated from consideration, including 13 articles that were written in a 
language other than English. 
Full-text versions of 465 articles were obtained, and 322 were eliminated electronically or by scanning 
hard copies. The remaining 143 articles underwent a close reading of the full text, and data extraction 
was undertaken for 86 articles, listed in Appendix 2 (online). Extracted data are presented in 
Appendix 3 (online).  A flowchart describing the systematic review process is given in Figure 1.  
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Background characteristics 
The publications included were drawn from a wide range of journals. Higher numbers of EVPI 
calculations have been observed in recent years. Nine studies were carried out alongside trials, with 
the remainder being pure modelling studies. Where stated, time frames over which the technology 
under study was expected to remain useful varied from one to 30 years, with 38 out of 86 studies 
opting for 10 years. WTP thresholds for quality-adjusted life year (QALY) outcomes ranged from £500 
to nearly £80,000. Seven articles reported EVSI calculations in addition to EVPI results. Other key 
characteristics of the included studies are listed in Table 1.  
Research recommendations 
Categorical recommendations were rare, with only a few explicitly using the term ‘recommend’; 
however, many were implicit. Where an absolute, rather than a comparative, value judgment was 
applied, the EVPI was described as ‘low’, ‘small’, ‘high’, ‘large’ or ‘substantial’. Of the 86 included 
articles, 13 suggested no further research, whilst 66 were more positive (10 implicitly through 
parameter research recommendations, two on the basis of factors other than VoI results and the 
remainder on the basis of the EVPI value). Seven made no recommendation. The costs of carrying 
out research—an essential requirement for making a robust recommendation—were not frequently 
assessed with few articles making reference to actual figures. These estimates varied substantially 
(for example, as low as €200,000 (£172,000) and as high as $27.1 million (£17.5 million) for a phase 
III clinical trial), as might be expected for varying trial designs and settings.  
The classification of recommendations is illustrated in Figure 2. Owing to the extensive range of EVPI 
values observed, the graphs are plotted on a natural logarithmic scale. For presentation purposes, the 
scale has been truncated and study numbers are omitted. The graph indicates that stronger belief that 
no further research should be pursued is clustered at lower EVPI values, while a strong belief that 
research should be carried out tends to be more common towards higher EVPI values. Collapsing the 
data into binary categories of no further research (including all three negative categories) and any 
other recommendation (Figure 3), suggests a cut-off point around an EVPI value of £250,000 below 
which research was not typically recommended. Between £250,000 and £2 million, recommendations 
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were variable, while EVPI values over £2 million did not typically attract recommendations against 
further research.  
Statistical analysis 
The statistical analysis showed EVPI to be the only significant predictor (p=0.007) of research 
recommendations. No interaction terms were found to be significant at the 0.05 level. A restricted 
model containing EVPI as the only explanatory variable (‘EVPI only’) fitted the data significantly better 
than a constant-only (empty) model (Likelihood ratio: 37.8; p<0.000). The unrestricted model 
containing all the available variables (‘full’ model) achieved a small, non-significant improvement in 
explanatory strength over the ‘EVPI only’ model (Likelihood ratio: 40.85, p=0.723). Stepwise selection 
also resulted in a model with EVPI as the only statistically significant parameter at significance levels 
up to 0.15.  
Results of the ‘EVPI only’ and ‘full’ models, in terms of changes in odds of a positive recommendation 
for a unit change in each explanatory variable are given in Table 2. In the ‘EVPI only’ model, an 
increase in EVPI by £1 million is associated with an increase in the odds of a positive research 
recommendation by 56% (95% CI: 13% to 115%, p=0.007). Predicted values of the probability of a 
positive recommendation at different values of EVPI are shown in Figure 4. At levels of EVPI up to 
£1.48 million, the probability of a study recommending research is less than 0.5. At £1.48 million, the 
probability of a positive recommendation reaches 0.5 (95% CI: 0.29 to 0.70), indicating that a 
threshold value above (below) which researchers are more (less) likely to recommend research exists 
roughly at £1.5 million. For EVPI values between £1.5 and £4 million, the probability is between 50% 
and 75%, while for higher EVPI values, in excess of £10 million, this probability is over 95%. While not 
statistically significant, the odds of a positive recommendation as calculated using the ‘full’ model 
were higher for studies on neoplasms, and studies funded by academic institutions and the industry 
compared to those sponsored by the government or medical charities. The odds of a positive 
recommendation were lower for studies the results of which relate to the UK, for studies that report 
QALYs and for studies published after 2007 (Appendix 4 online). Given that none of these variables 
were statistically significant predictors of the probability of a positive recommendation, we emphasise 
the discussion on the findings of the ‘full’ model is intended to provide indications, rather than firm 
conclusions. 
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Discussion 
Our exploration suggests that recommendations are reasonably consistent with EVPI values, with 
greater EVPI values attracting more positive recommendations for research. An empirical threshold 
value of £1.48 million was determined via a statistical analysis, above which the predicted likelihood 
of a positive recommendation exceeds 0.5. The use of an EVPI value alone to make an explicit firm 
recommendation to conduct further research would however be inappropriate; most positive 
recommendations also took  other factors into account, expressing the recommendation in terms of 
possible, rather than definite, benefits. 
Different factors may have a bearing on the interpretation of EVPI and subsequent recommendations, 
although none were found to be statistically significant in this study. Neoplasms appear to attract a 
higher rate of positive research recommendations than other disease areas, which could mirror 
societal factors; cancers are overrepresented in the media compared with other diseases [29] and 
societal interest in, and approval for, cancer research may influence authors. In the top ten 
therapeutic research areas focused on by pharmaceutical companies, cancer drugs outweigh other 
areas by a factor of at least 2.5 [30]; cancer research is well supported by multiple funding sources 
including charitable entities [31], and authors may be encouraged to make positive research 
recommendations by the likelihood of receiving research funding. Funding by industry sponsors is 
associated with the presentation of more positive cost-effectiveness results, a form of publication bias. 
[32] This study suggests that industry sponsors may be more likely than government sponsors to 
make positive recommendations based on their VoI results, which may tally well with commercial 
interests.  However, academic sponsors were also more likely than government sponsors to make 
positive recommendations.  Studies published before 2007 are more likely to give positive 
recommendations, which could be as a result of a more cautious stance towards recommending 
research in a period characterised by policies aimed to contain public expenditure.  Although there is 
a possibility that researchers naturally have a vested interest in recommending further research, this 
study does not provide any significant evidence to support this idea. Most of the identified studies 
were carried out with a view to informing treatment and research recommendations in the UK. The 
preponderance of studies originating from the UK is likely to have arisen as a result of national 
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guidelines, with NICE having formally advocated the use of VoI methods in England and Wales in 
2004. [33]  
As Eckermann et al [34] point out, in determining a threshold value of EVPI one needs to consider the 
costs of undertaking research, which, in turn, depends on the type and size of the proposed research 
programme. The costs of further research can vary significantly. In 2005, clinical trials cost a total of 
$24 billion in the US, representing a mean cost of just under £3 million per trial [35], while in the UK 
£950 million was spent, at an average of approximately £100,000 per trial. [36] However, the 
reasoning behind making a particular recommendation was rarely related to the actual costs of 
carrying out research, with few studies explicitly citing these costs.  One paper referred to the 
expected high costs of running a trial in that particular disease area and the authors were negative 
about further research even with a relatively high EVPI value of £10.76 million [22]; the authors also 
took into account the fact that the drug was likely to come off patent during any trial. Costs that were 
cited covered a broad range, indicating that there is substantial variability around the estimates of trial 
costs. However, although not explicitly mentioned, the observed values at which research is typically 
recommended correspond reasonably well with average costs of running trials; it appears that authors 
implicitly acknowledge probable trial costs. The region of uncertainty between £250,000 and £2 
million, where recommendations were not consistent, very plausibly covers typical trial costs. This 
potential variation in trial costs means that the ‘threshold’ we have identified cannot be extrapolated to 
be treated as a rule that should be followed in all cases. 
The study has both strengths and weaknesses. It represents the first attempt at deriving an empirical 
‘threshold’ value of EVPI. The search strategy was rigorous and thorough in order to identify the 
applied VoI literature. Owing to the variable quality of the suppliers’ boolean logic implementations, 
and the restriction to English language articles only, some relevant material may have been 
overlooked; however, this is not likely to alter the broad conclusions.  Material from the grey literature 
was not sought and this may have led to the omission of some relevant material. It is not clear 
whether grey material is more or less likely to influence decision making. However, as the 
interpretation of EVPI values in terms of further recommendations for research is at the discretion of 
the researcher, we do not believe it is likely that there is a systematic reason for EVPI values to 
appear in the grey literature only. The texts examined covered a range of countries and cost years. 
11 
 
EVPI values were converted to a common currency but not to a common cost year, which may have 
affected the observed threshold. However, we do not believe that this limitation would have had a 
substantial effect on the outcome; recommendations against further research were drawn from a wide 
range of years, and publication year did not have a significant effect on the likelihood of 
recommendation. Inevitably, there was a level of subjectivity in the classification schema for the 
recommendations, and also in the decision of which EVPI value to choose when multiple values were 
given.  
Conclusions 
Empirical analysis on the basis of the identified literature suggests that calculated EVPI values are a 
key driver of researchers’ recommendations for further research. Factors other than EVPI, including 
disease area, funder, study location, publication year and outcome reported, may have a bearing on 
recommendations for further research, however none of them reached statistical significance in the 
analysis. A threshold EVPI value above which the predicted probability of a positive recommendation 
exceeds 0.5 was found to be around £1.48 million, though there is much variation around this value.   
EVPI should not be seen as a substitute for EVSI, which is a more realistic and informative measure 
of the value of pursuing ‘real-world’ sample research. However, we believe that there is a role for 
EVPI in research prioritisation, in providing a simple criterion which can indicate the situations where 
pursuing further research would be wasteful.  
This study offers insights into factors and considerations that may affect recommendations made in 
light of EVPI values. Unless such factors and considerations are understood and made explicit, there 
will always be a risk that researchers’ recommendations for further studies will be treated as 
subjective and opaque.  
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Table 1. Characteristics of the 86 included studies 
Characteristic Number (%) 
Funder  
 Government 53 (61.6) 
 Industry-related 17 (19.8) 
 Academic 14 (16.3) 
 Charity 2 (2.3) 
Disease group  
 Circulatory system 20 (23.3) 
 Neoplasms 19 (22.1) 
 Musculoskeletal system 8 (9.3) 
 Genitourinary system 5 (5.8) 
 Other 34 (39.5) 
Outcome measure  
 QALYs 74 (86.0) 
 Life-years gained 7 (8.1) 
 Other 5 (5.8) 
Currency  
 Sterling 48 (53.5) 
 US$ 16 (18.6) 
 Euros 13 (15.1) 
 Can$ 6 (7.0) 
 Other 3 (3.5) 
Location  
 UK 46 (53.5) 
 US 13 (15.1) 
 Netherlands 12 (14.0) 
 Canada 6 (7.0) 
 Other 9 (10.5) 
Publication date  
 2000–2005  12 (14.0) 
 2006–2010  74 (86.0) 
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Table 2. Results of 'EVPI only' and 'full' models 
Model Predictor variables Odds ratio SE P>|z| 
95% Confidence 
interval 
Likeliho
od ratio 
McFadden's 
adjusted R
2
 
Pr>LR 
Akaike 
Information 
Criterion 
Bayesian 
Informatio
n Criterion 
EVPI 
only 
EVPI 1.558 0.254 0.007 1.131 2.145 37.8 0.463 0.000 0.456 -33.34 
Full 
model 
EVPI 1.679 0.329 0.008 1.143 2.466 
39.85 0.176 0.723 0.700 -5.22 
Neoplasms 1.866 2.072 0.574 0.212 16.442 
Funder (base category: 
government/charity) 
          
Industry 1.431 2.603 0.844 0.040 50.601 
Academia 4.549 7.143 0.335 0.210 98.746 
United Kingdom 0.442 0.472 0.444 0.055 3.579 
QALYs 0.713 0.842 0.775 0.070 7.217 
Publication year (base 
categ.  ‘before 2007') 
  
2007-2008 0.689 0.836 0.759 0.064 7.428 
2009-2010 0.286 0.349 0.305 0.026 3.133 
Statistic testing the null hypothesis that the addition of variables does not contribute to improved explanatory power (ie. increased values of log-likelihood)   
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Figure 1. Flowchart 
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Closer reading 
of pdf to identify 
relevant articles 
2078 potentially relevant abstracts 
identified via abstract database 
searches and 560 via full-text 
searches 
2497 potentially relevant abstracts to 
screen 
1990 not relevant from abstract (e.g. non-
medical context) 
13 not in English 
25 not relevant confirmed by consulting EED 
4 authors confirmed not relevant 
 
465 full text articles obtained 
full text articles obtained 
cles obtained 
143 with relevant usage of “perfect” 
183 did not mention “perfect” 
123 only mentioned “perfect” in an irrelevant 
context 
16 hard copies not relevant 
32 not examples of applied EVPI calculations 
7 duplicate reports of study 
6 not peer-reviewed publications 
1 only cited EVSI results 
2 methodological focus 
1 clinical decision making 
8 reported only individual EVPI values 
86 articles included 
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Figure 2. Recommendations for further research by EVPI value; values are plotted on a log scale. 
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Figure 3. Recommendations for further research collapsed into binary ‘no further research’ versus 
any other recommendation; values are plotted on a log scale. 
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Figure 4. Predicted probability of positive recommendation at different EVPI values obtained 
from ‘EVPI only’ model. 
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Appendix 1. Systematic searches performed 
Bibliographic database searches 
Medline (29 July 2011, 1990-2010, lemmatization on, via Web of Knowledge) 
Search 
number 
Search 
No. of 
results 
#1 Topic=(cost) 254034 
#2 Topic=("Value of information") 253 
#3 Topic=("Value of * information") 370 
#4 Topic=("Value of * * information") 131 
#5 Topic=(EVPI*) 31 
#6 #5 OR #4 OR #3 OR #2 677 
#7 #6 AND #1 220 
#8 MeSH Heading=(Cost benefit analysis) 42894 
#9 MeSH Heading:exp=(Decision making) 78616 
#10 MeSH Heading:exp=(Decision support techniques) 45358 
#11 MeSH Heading:exp=(Decision theory) 7726 
#12 MeSH Heading:exp=(Decision trees) 7254 
#13 MeSH Heading=(Models econometric) 3333 
#14 MeSH Heading=(Models economic) 4134 
#15 MeSH Heading=(Models statistical) 49631 
#16 MeSH Heading:exp=(Health care rationing) 8483 
#17 MeSH Heading:exp=(Health care costs) 36673 
#18 MeSH Heading:exp=(Health priorities) 6766 
#19 MeSH Heading:exp=(Health policy) 60902 
#20 MeSH Heading=(Economics Medical) 2276 
#21 MeSH Heading:exp=(Markov chains) 6650 
#22 MeSH Heading:exp=(Uncertainty) 3709 
#23 MeSH Heading:exp=(Delivery of health care) 534223 
22 
 
#24 
#23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR 
#14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 731008 
#25 Topic=("perfect information") 99 
#26 Topic=(value of information) 57807 
#27 #26 OR #25 57833 
#28 #27 AND #24 AND #1 1772 
#29 #28 OR #7 1819 
 
 
Web of Science (29 July 2011, 1990-2010, lemmatization on, via Web of Knowledge) 
Search 
number 
Search 
No. of 
results 
# 1 Topic=("value of information")  898 
# 2 Topic=("value of * information")  756 
# 3 Topic=("value of * * information")  338 
# 4 Topic=(EVPI*)  48 
# 5 Topic=(cost)  441108 
# 6 #4 OR #3 OR #2 OR #1  1790 
# 7 #6 AND #5  511 
# 8 
#6 AND #5  
Refined by: [excluding] Web of Science Categories=( 
EVOLUTIONARY BIOLOGY OR COMPUTER SCIENCE THEORY 
METHODS OR OPERATIONS RESEARCH MANAGEMENT 
SCIENCE OR SURGERY OR GEOGRAPHY PHYSICAL OR 
MANAGEMENT OR ZOOLOGY OR ENGINEERING INDUSTRIAL 
OR AGRICULTURAL ECONOMICS POLICY OR 
ENVIRONMENTAL SCIENCES OR ENGINEERING CHEMICAL 
OR MATHEMATICAL COMPUTATIONAL BIOLOGY OR 
ENGINEERING MECHANICAL OR MATHEMATICS APPLIED OR 
COMPUTER SCIENCE INFORMATION SYSTEMS OR MINING 
MINERAL PROCESSING OR TRANSPORTATION OR BIOLOGY 
OR INFORMATION SCIENCE LIBRARY SCIENCE OR 
FORESTRY OR ROBOTICS OR AGRICULTURE DAIRY ANIMAL 
SCIENCE OR ENERGY FUELS OR PLANT SCIENCES OR 
BIOCHEMISTRY MOLECULAR BIOLOGY OR ENGINEERING 
MANUFACTURING OR SOIL SCIENCE OR BUSINESS OR 
THERMODYNAMICS OR BUSINESS FINANCE OR CHEMISTRY 
115 
23 
 
ANALYTICAL OR EDUCATION SCIENTIFIC DISCIPLINES OR 
COMPUTER SCIENCE SOFTWARE ENGINEERING OR 
FISHERIES OR ENGINEERING OCEAN OR AGRONOMY OR 
GEOGRAPHY OR ENTOMOLOGY OR ECOLOGY OR GEOLOGY 
OR ERGONOMICS OR METEOROLOGY ATMOSPHERIC 
SCIENCES OR INTERNATIONAL RELATIONS OR 
GEOCHEMISTRY GEOPHYSICS OR COMPUTER SCIENCE 
ARTIFICIAL INTELLIGENCE OR LAW OR IMAGING SCIENCE 
PHOTOGRAPHIC TECHNOLOGY OR LIMNOLOGY OR 
ENVIRONMENTAL STUDIES OR MATERIALS SCIENCE 
CHARACTERIZATION TESTING OR MATERIALS SCIENCE 
MULTIDISCIPLINARY OR ENGINEERING CIVIL OR 
TELECOMMUNICATIONS OR METALLURGY METALLURGICAL 
ENGINEERING OR ENGINEERING ELECTRICAL ELECTRONIC 
OR VETERINARY SCIENCES OR MINERALOGY OR 
ENGINEERING PETROLEUM OR AGRICULTURAL 
ENGINEERING OR GEOSCIENCES MULTIDISCIPLINARY OR 
AGRICULTURE MULTIDISCIPLINARY OR SOCIAL ISSUES OR 
TRANSPORTATION SCIENCE TECHNOLOGY OR COMPUTER 
SCIENCE CYBERNETICS OR WATER RESOURCES OR 
ENGINEERING ENVIRONMENTAL OR URBAN STUDIES OR 
ENGINEERING MULTIDISCIPLINARY OR AUTOMATION 
CONTROL SYSTEMS ) AND [excluding] Web of Science 
Categories=( PLANNING DEVELOPMENT ) AND [excluding] 
Subject Areas=( BUSINESS ECONOMICS OR COMPUTER 
SCIENCE )  
 
 
EMBASE (30 July 2011, via Ovid) 
 
Search 
number 
Search 
No. of 
results 
1 cost.mp. 420222 
2 "value of information".mp. 566  
3 "value of of information".mp. 1195  
4 "value of of of information".mp. 1543  
5 evpi*.mp. 43  
6 2 or 3 or 4 or 5 1554  
7 1 and 6 345  
8 exp "cost benefit analysis"/ 55210  
9 exp "cost effectiveness analysis"/ 73437  
24 
 
10 exp "cost utility analysis"/ 3537  
11 exp decision making/ 106853  
12 exp medical decision making/ 57338  
13 exp decision support system/ 8590  
14 exp decision theory/ 1345  
15 exp "decision tree"/ 3793  
16 exp statistical model/ 71792  
17 exp health care organization/ 866316  
18 exp "health care cost"/ 162180  
19 exp health care planning/ 65978  
20 exp health care policy/ 114734  
21 exp health economics/ 498628  
22 exp probability/ 45938  
23 exp uncertainty/ 3974  
24 exp health care delivery/ 1406295  
25 
8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
or 21 or 22 or 23 or 24 
2533843  
26 "perfect information".mp. 143  
27 
(value adj4 information).mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device manufacturer, 
drug manufacturer, device trade name, keyword] 
2980  
28 26 or 27 3026  
29 1 and 25 and 28 389  
30 limit 29 to yr="1990 - 2010" 353 
 
 
The Cochrane Library (2 August 2011, 1990-2010) 
 
Search Search No. of 
25 
 
number results 
#1 "value of information" or "perfect information" or (evpi*) 106 
#2 MeSH descriptor Cost-Benefit Analysis explode all trees 1158 
#3 MeSH descriptor Decision Making explode all trees 1932 
#4 MeSH descriptor Decision Support Techniques explode all trees 2645 
#5 MeSH descriptor Decision Theory explode all trees 727 
#6 MeSH descriptor Models, Economic explode all trees 1269 
#7 MeSH descriptor Models, Statistical explode all trees 10014 
#8 MeSH descriptor Health Care Rationing explode all trees 77 
#9 MeSH descriptor Health Care Costs explode all trees 5149 
#10 MeSH descriptor Health Policy explode all trees 381 
#11 MeSH descriptor Economics, Medical explode all trees 91 
#12 MeSH descriptor Markov Chains explode all trees 1267 
#13 MeSH descriptor Delivery of Health Care explode all trees 28534 
#14 
(#2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR 
#11 OR #12 OR #13) 
46484 
#15 value near/4 information 318 
#16 perfect information 277 
#17 (#15 OR #16) 542 
#18 cost 35787 
#19 (#14 AND #17 AND #18) 155 
#20 (#1 OR #19), from 1990 to 2010 197 
 
 
CINAHL (4 August 2011, via EBSCOHost) 
 
Search 
number 
Search 
No. of 
results 
26 
 
S1 "Value of information" 127 
S2 "Value of * information" 230 
S3 "value of * * information" 288 
S4 EVPI* 12 
S5 S1 or S2 or S3 or S4 288 
S6 cost 52045 
S7 S5 and S6 80 
S8 (MH "Costs and Cost Analysis+") OR (MH "Cost Benefit Analysis") 43453 
S9 (MH "Decision Making+") 40667 
S10 (MH "Decision Support Techniques+") 1128 
S11 (MH "Models, Statistical") 5859 
S12 (MH "Health Resource Allocation") 4808 
S13 (MH "Health Care Costs+") 18452 
S14 (MH "Health Policy+") 38575 
S15 (MH "Health Care Delivery+") 129986 
S16 (S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15) 217343 
S17 "perfect information" 29 
S18 value of information 577 
S19 S17 or S18 580 
S20 S6 and S16 and S19 82 
S21 S7 or S20 (Limiters- Published Date from: 19900101-20101231) 89 
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Full-text searches 
AdisOnline (5 August 2011) 
Search  
No. of 
results 
evpi 21 
"expected value of perfect information" 200 
Total after deduping 200 
 
HighWire Press (11 August 2011) 
Search  
No. of 
results 
evpi  (all words anywhere in article) 
 In HighWire-hosted journals + Medline 
From Jan 1990 to Dec 2010 
106 
“expected value of perfect information” (exact phrase anywhere in article) 
 In HighWire-hosted journals + Medline 
From Jan 1990 to Dec 2010 
139 
Total after deduping 156  
 
Cambridge Journals Online (11 August 2011) 
Search  
No. of 
results 
 Perform new search: evpi 
 Anywhere: evpi 
 Exclude book reviews from results: Yes 
 Restrict search by date range: 01-Jan-1990 to 31-Dec-2010 
 Journal: All 
11 
 Perform new search: "expected value of perfect information"  
 Exclude book reviews from results: Yes 
 Restrict search by date range: 01-Jan-1990 to 31-Dec-2010 
 Journal: All 
 Anywhere: "expected value of perfect information" 
15 
28 
 
 
Total after deduping 18  
 
IngentaConnect (11 August 2011) 
Search  
No. of 
results 
(All Fields including Full Text contains ‘"expected value of perfect 
information"’) 
66 
(All Fields including Full Text contains ‘evpi’) 44 
Total after deduping 70  
 
ScienceDirect (11 August 2011) 
Search  
No. of 
results 
pub-date > 1989 and pub-date < 2011 and ALL("expected value of perfect 
information") or ALL(evpi)[Journals(Immunology and Microbiology,Medicine 
and Dentistry,Neuroscience,Nursing and Health Professions,Pharmacology, 
Toxicology and Pharmaceutical Science)] 
59 
 
Scholar (13 August 2011) 
Search  
No. of 
results 
Cost AND (EVPI OR “expected value of perfect information”) 1990–2010 718 
Following first screening 179 
Total after deduping 175 
 
Health Technology Assessment (30 September 2011) 
Search  
No. of 
results 
29 
 
“expected value of perfect information” OR evpi 76 
Total after deduping and preliminary screening 14 
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Appendix 3. Data extracted from included articles (references appear in Appendix 2). 
 
First author Publication 
year 
Funder Location Individual 
EVPI 
Population 
EVPI (£) 
WTP 
threshold 
Outcome 
measure 
Currency Timeframe 
Armstrong [1] 2009 Government UK  5300000 20000 QALY GBP not stated 
Bansback [2] 2004 Academic UK  246000 30000 QALY GBP 1 year 
Black [3] 2009 Government UK  600000000 30000 QALY GBP 10 years 
Bojke [4] 2008 Government UK  6900000 30000 QALY GBP 10 years 
Bravo [5] 2007 Government UK  23046814 not stated QALY GBP 10 years 
Burch [6] 2008 Government UK  16000000 30000 QALY GBP 8 years 
Carlson [7] 2009 Industry-related US 381 31400000 100000 QALY USD 5 years 
Carlton [8] 2008 Government UK  45000000 17000 QALY GBP 10 years 
Castelnuovo [9] 2006 Government UK  16900000 30000 QALY GBP 15 years 
Castelnuovo [10] 2008 Industry-related UK  170000000 30000 QALY GBP 10 years 
Claxton [11] 2001 Charity US  339000000 50000 QALY USD averaged 
over 2 to 8 
40 
 
years 
Clegg [12] 2010 Government UK  14000000 23000 QALY GBP 10 years 
Colbourn [13] 2007 Government UK  67300000 25000 QALY GBP 10 years 
Coyle [14] 2008 Government Canada 3247 480000000 50000 QALY Can$ 10 years 
Da Silveira [15] 2008 Academic US  24000000 5000 per 
improvemen
t in 
swallowing 
graded by 
the 
dysphagia 
score 
USD 20 years 
Dong [16] 2007 Industry-related UK 21.4 8300000 30000 QALY GBP 10 years 
Eddama [17] 2010 Government UK almost 
£100.00 per 
woman 
1033400 30000 per 
prevention 
of preterm 
birth 
GBP 1 year 
Ehlers [18] 2009 Government Denmark  1000000 30000 QALY GBP 20 years 
Fenwick [19] 2006 Industry-related UK 350 48000000 20000 life year GBP 15 years 
Fleurence [20] 2007 Government UK  608000000 30000 QALY GBP 5 years 
Forbes [21] 2002 Government UK 800 10700000 30000 life years 
gained 
GBP 5 years 
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Fox [22] 2007 Government UK 157 6200000 30000 QALY GBP 7 years 
Galani [23] 2008 Government Switzerla
nd 
198 6785783 5000 QALY CHF 10 years 
Genders [24] 2009 Government Netherla
nds 
46 per 
woman 
380000000 80000 QALY euros 5 years 
Ginnelly [25] 2005 Government UK  2240000 30000 QALY GBP 10 years 
Girling [26] 2007 Industry-related UK 395 28000000 30000 QALY GBP 5 years 
Gold [27] 2009 Charity US  13800000 100000 QALY USD 5 years 
Grant [28] 2008 Government UK  300000000 30000 QALY GBP annual? 
Griebsch [29] 2007 Government UK  744000 50000 timely 
diagnosis of 
“lifethreaten
ing” 
CHD 
GBP 5 years 
Groot Koerkamp 
[30] 
2010 Government Netherla
nds 
249 11000000 80000 QALY euros 5 years 
Groot Koerkamp 
[31] 
2008 Government Netherla
nds 
2.1 365000 80000 QALY euros 10 years 
Grutters [32] 2008 Government Netherla
nds 
87 100000000 40000 QALY euros 10 years 
Grutters [33] 2010 Industry-related Netherla 7784 22000000 80000 QALY euros 10 years 
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nds 
Hassan [34] 2009 Industry-related US 520 56777030 100000 life years 
gained 
USD 10 years 
Hassan [35] 2010 Academic US 16647 1099357520 150000 life years 
gained 
USD 5 years 
Hassan [36] 2009 Industry-related US 216 15291170112 100000 life years 
gained 
USD 5 years 
Henriksson [37] 2006 Government sweden 0.33 115000 50000 QALY euros 10 years 
Hewitt [38] 2009 Government UK  40075803 30000 QALY GBP 10 years 
Hoomans [39] 2009 Academic UK  13400000 30000 QALY GBP 1.5 years 
Iglesias [40] 2006 Academic UK  126700 500 QALY GBP 10 years 
Jansen [41] 2010 Industry-related UK  80000 20000 QALY GBP 30 years 
Karnon [42] 2002 Government UK 239.08 7045615 5000 QALY GBP 5 years 
Kim [43] 2010 Academic South 
Korea 
 12000000000
0 
8000000 QALY KRW 5 years 
Knight [44] 2004 Government UK 53 159000 30000 QALY GBP 1 year 
Knowles [45] 2005 Government UK  750000 5000 timely 
diagnosis 
GBP 5 years 
Kulkarni [46] 2009 Academic Canada 28220 275000000 50000 QALY Can$ 1 year 
Martikainen [47] 2005 Industry-related Finland  4100000 32471 QALY euros 10 years 
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McKenna [48] 2009 Government UK 440.16 48741220 30000 QALY GBP 10 years 
McKenna [49] 2010 Government UK 2694 696178334 30000 QALY GBP 10 years 
Meenan [50] 2007 Government US <100 20000000 50000 QALY USD 1 year 
Meltzer [51] 2009 Industry-related US  30800000000
0 
50000 QALY USD 20 years 
Miners [52] 2009 Industry-related UK 44000 20000000 30000 QALY GBP 10 years 
Oostenbrink [53] 2008 Industry-related Netherla
nds 
1070 96000000 20000 QALY euros 1 year? 
Pandor [54] 2004 Government UK  3656 2000 life year 
gained 
GBP 5 years 
Payne [55] 2000 Government UK  200000 20000 life years 
saved 
GBP 5 years 
Petrou [56] 2010 Industry-related UK 65.73 9100000 20000 QALY GBP 10 years 
Philips [57] 2006 Academic UK 43 20032000 30000 QALY GBP 10 years 
Pohar [58] 2009 Government Canada 19157 19000000 50000 QALY Can$ 1 year 
Quinn [59] 2007 Industry-related Canada 1821 76482000 50000 QALY USD 1 year 
Ramsey [60] 2008 Government US  46000000 50000 QALY USD 10 years 
Rao [61] 2009 Industry-related UK  35554.50 50000 QALY USD 4 years 
Rodgers [62] 2008 Government UK 635.01 5465967 30000 QALY GBP 5 years 
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Rogowski [63] 2009 Government UK  10762438 30000 QALY GBP 10 years 
Rojnik [64] 2008 Industry-related Slovenia 23  115000000 20000 QALY euros 10 years 
Shepherd [65] 2010 Government UK  12500000 20000 QALY GBP 10 years 
Singh [66] 2008 Academic Canada 32.59 16300000 20000 per 
inappropriat
e ACS 
discharge 
prevented 
Can$ 1 year 
Smith [67] 2007 Government US 532 1666224 100000 QALY USD 10 years 
Smits [68] 2010 Government US 1759 7000000000 75000 QALY USD  
Somerville [69] 2008 Government UK 148 6553619 30000 QALY GBP 10 years 
Speight [70] 2006 Government UK  277000000 30000 QALY GBP 10 years 
Spronk [71] 2008 Academic Netherla
nds 
1743 2400000000 75000 QALY USD 10 years 
Spronk [72] 2008 Academic Netherla
nds/US 
30 39000000 50000 QALY euros 5 years 
Stevenson [73] 2010 Government UK 53.50 64000000 not 
explicitly 
stated in 
context of 
EVPI   
QALY GBP 10 years 
Tappenden [74] 2004 Government UK 8855 86208936 30000 QALY GBP 10 years 
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Teerawattananon 
[75] 
2007 Government Thailand  26000000000
0 
650000 QALY Thai baht 10 years 
TEN [76] 2009 Government Netherla
nds 
32 27000000 40000 QALY euros 10 years 
Tholen [77] 2010 Government Netherla
nds 
318 1500000000 50000 QALY euros 5 years 
Tran [78] 2010 Government Canada 172 295000000 50000 QALY Can$ 1 year 
Van der Sluis [79] 2010 Academic Netherla
nds 
282 423000000 80000 QALY euros 5 years 
Van Loon [80] 2009 Academic Netherla
nds 
810 3245786 75000 QALY USD 5 years 
Wailoo [81] 2008 Government UK  2000000 30000 QALY GBP 15 years 
Weatherly [82] 2009 Government UK 183 33000000 20000 QALY GBP 5 years 
Welton [83] 2008 Government UK  932000000 30000 QALY GBP 10 years 
Wight [84] 2003 Government UK 125 812500 20000 QALY GBP 5 years 
Wilson [85] 2010 Academic UK  18800000 20000 QALY GBP 10 years 
Xie [86] 2009 Government Canada 0 0 30000 QALY Can$  
 
46 
 
Appendix 4. Predicted probability of positive recommendation at different EVPI 
values for ‘full’ model, holding all covariates constant at baseline values 
 
Figure 1. Predicted probability of positive recommendation at different EVPI values by country 
classification 
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Figure 2. Predicted probability of positive recommendation at different EVPI values by disease 
classification 
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Figure 3. Predicted probability of positive recommendation at different EVPI values by study funder 
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Figure 4. Predicted probability of positive recommendation at different EVPI values by outcome 
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Figure 5. Predicted probability of positive recommendation at different EVPI values by publication year 
 
 
 
 
